高级检索
当前位置: 首页 > 详情页

Risk factors for tumor recurrence in patients with pT3N0M0 thoracic esophageal squamous cell carcinoma after esophagectomy.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China [2]Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China [3]Department of thoracic surgery, Fourth Hospital of Hebei Medical University & Hebei Cancer Hospital, Shijiazhuang, China [4]Department of Radiation Oncology, Fourth Hospital of Hebei Medical University & Hebei Cancer Hospital, Shijiazhuang, China [5]Department of Radiation Oncology, Hebei University Affiliated hospital, Baoding, China [6]Department of CT/MRI, Fourth Hospital of Hebei Medical University & Hebei Cancer Hospital, Shijiazhuang, China
出处:
ISSN:

关键词: Esophageal squamous cell carcinoma esophagectomy recurrence adjuvant radiotherapy adjuvant chemotherapy distant metastasis

摘要:
To analyze the factors contributing to recurrence in patients with pT3N0M0 thoracic esophageal squamous cell carcinoma (ESCC). Patients with pT3N0M0 thoracic ESCC who underwent esophagectomy from January 2008 to December 2012 were included retrospectively. The last date of follow-up was 1 December 2016. Multivariate proportional hazard Cox models were used to identify factors associated with total (i.e., any) recurrence (TR), locoregional recurrence (LR), and distant metastasis (DM). A total of 692 patients were included. The median follow-up was 53 months (range: 3-107). The 3- and 5-year TR, LR, and DM rates were 35.8% and 41.0%, 28.7% and 32.1%, and 16.8% and 21.1%, respectively. The Cox analyses showed that the tumor location, number of dissected lymph nodes, and postoperative therapies were significantly associated with LR. The subgroup analysis showed that postoperative therapies could significantly decrease LR in the mediastinum but not in the neck and upper abdomen regions. The recurrence rate of pT3N0M0 thoracic ESCC patients was high, especially for LR in the mediastinum. Postoperative therapies can significantly reduce the incidence of mediastinal recurrence.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 药学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 药学
JCR分区:
出版当年[2020]版:
Q4 PHARMACOLOGY & PHARMACY Q4 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q4 MEDICINE, RESEARCH & EXPERIMENTAL Q4 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Department of Radiation Oncology, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China [2]Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, China
通讯作者:
通讯机构: [4]Department of Radiation Oncology, Fourth Hospital of Hebei Medical University & Hebei Cancer Hospital, Shijiazhuang, China [*1]Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, No. 12, Jiankang road, Shijiazhuang, Hebei Province 050011, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:15072 今日访问量:0 总访问量:949 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北大学附属医院 技术支持:重庆聚合科技有限公司 地址:保定市莲池区裕华东路212号